Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now full pipeline

Kidney Transplantation: full-pipeline trial registry

8 of 35 indexed Kidney Transplantation trials are currently recruiting.

Corpus placement: #435 of 28,707 conditions by registered trial count.

35 US clinical trials · 8 currently recruiting · #435 of 28,707 conditions by registered trial count

Kidney Transplantation: 35 US clinical trials tracked, 8 recruiting.

Kidney Transplantation is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 4 of these trials.

Enrollment posture brief

Registry condition kidney-transplantation

OPEN 8 | RECR 23% | LATE 8 | EARLY 12 | RANK #435 | SPON 4

Nearest open-share peer: Atherosclerosis (23% recruiting · 70 trials)

Cannabis Use Disorder71.4%Cirrhosis, Liver60%Kidney Transplantation (this)23%Carcinoma, Renal Cell17.1%Advanced Lymphoma8.6%
Open-enrollment share among volume-matched conditions near Kidney Transplantation

Kidney Transplantation lists 8 open slots (23% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Kidney Transplantation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Kidney Transplantation is recruiting below its size-band peers.

    8 of 35 indexed trials (22.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Kidney Transplantation trials is spread across many organizations.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 4 of 35 trials (11.4%). 26 distinct sponsors appear on at least one study for this condition label.

  3. Typical Kidney Transplantation enrolment sits around 88 participants.

    Median target enrolment is 88 among the 34 trials that report a genuine target (sentinel values excluded). 18 of those (52.9%) plan for fewer than 100 participants.

  4. Kidney Transplantation research is mostly interventional.

    30 interventional and 5 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 27Phase 33Phase 45

Open and recent trials

35 total, page 1 of 1

RECRUITING NA 3,306 participants

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

University of British Columbia

NCT03674307

RECRUITING Phase 4 350 participants

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

Mayo Clinic

NCT06568549

RECRUITING NA 100 participants

Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision

Hennepin Healthcare Research Institute

NCT05879302

RECRUITING Phase 1 50 participants

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

United Therapeutics

NCT06878560

RECRUITING Phase 1 50 participants

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

United Therapeutics

NCT07224763

RECRUITING Phase 2 45 participants

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Alexion Pharmaceuticals

NCT06744647

RECRUITING Phase 2 34 participants

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Singulera Therapeutics

NCT06552169

RECRUITING NA 15 participants

Prehabilitation for Kidney Transplant Candidates

The Methodist Hospital Research Institute

NCT06886256

ACTIVE NOT RECRUITING NA 206 participants

APOL1 Genetic Testing Program for Living Donors

Northwestern University

NCT04910867

ACTIVE NOT RECRUITING NA 70 participants

Watermelon/UBIQuinone Study

University of California, San Francisco

NCT04972552

ACTIVE NOT RECRUITING Phase 2 30 participants

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

Amit D Tevar, MD

NCT03809533

ACTIVE NOT RECRUITING Phase 4 28 participants

Envarsus XR® in Adolescent Renal Transplant Recipients

University of California, Los Angeles

NCT03266393

ACTIVE NOT RECRUITING Phase 2 18 participants

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

ITB-Med

NCT04803058

COMPLETED Phase 3 850 participants

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Astellas Pharma Europe

NCT02118896

COMPLETED Phase 4 720 participants

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

Hoffmann-La Roche

NCT00087581

COMPLETED Phase 4 501 participants

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Astellas Pharma

NCT00113269

COMPLETED NA 350 participants

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00007787

COMPLETED Phase 2 338 participants

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Pfizer

NCT00483756

COMPLETED Phase 2 323 participants

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

Astellas Pharma

NCT00543569

COMPLETED 307 participants

Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01289717

COMPLETED NA 224 participants

Does an Abdominal Wall Nerve Block During Surgery Help Reduce Pain From Kidney Transplantation?

The Cleveland Clinic

NCT05280197

COMPLETED NA 170 participants

Intervention to Improve Adherence in Teen Kidney Transplant

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT01356277

COMPLETED NA 116 participants

Vitamin D Replacement After Kidney Transplant

University of Nebraska

NCT00748618

COMPLETED Phase 3 100 participants

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00000935

COMPLETED 100 participants

Survey of Adherence to Immunosuppression and Other Medications in Kidney Transplant Patients

State University of New York - Downstate Medical Center

NCT00433134

COMPLETED NA 88 participants

HLA-Identical Sibling Renal Transplant Tolerance

Northwestern University

NCT00619528

COMPLETED 83 participants

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Pfizer

NCT01375127

COMPLETED Phase 4 80 participants

Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation

Vanderbilt University

NCT00305396

COMPLETED Phase 1 59 participants

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Novartis Pharmaceuticals

NCT02217410

COMPLETED Phase 2 46 participants

Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

Pfizer

NCT00263328

COMPLETED Phase 3 45 participants

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

Novartis Pharmaceuticals

NCT00098241

COMPLETED 24 participants

Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant

Weill Medical College of Cornell University

NCT01271465

COMPLETED Phase 1 10 participants

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

University of Wisconsin, Madison

NCT00078559

COMPLETED Phase 1 8 participants

Tolerance by Engaging Antigen During Cellular Homeostasis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03504241

COMPLETED

Intraperative Assessment of Renal Perfusion Using Infrared Imaging

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00595179

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 7
Phase 3 3
Phase 4 5

Named interventions

Most-linked intervention names on Kidney Transplantation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tacrolimus Drug
5 trials
mycophenolate mofetil Drug
3 trials
basiliximab Drug
2 trials
CP-690,550 Drug
2 trials
alemtuzumab Drug
2 trials
tacrolimus Drug
2 trials
Cyclosporine Drug
2 trials
Sirolimus Drug
2 trials

US sites by state

Facility locations filed on Kidney Transplantation trials. A trial with sites in several states counts in each.

Illinois 10 trials
California 10 trials
New York 8 trials
Ohio 7 trials
Maryland 7 trials
Florida 7 trials
Colorado 7 trials
New Jersey 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Kidney Transplantation page

35 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Transplantation condition card totals 35 registered trials; most-linked intervention Tacrolimus; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.